This Diverse Therapeutics Innovator Is Experiencing Huge Growth, Here's Why...

See why now could be the best time to start your research on HippoFi, Inc. (OTCPK: ORHB).

Price Targets





Potential support at $0.0231


HippoFi Ships International Orders and Expects Sales to Exceed $20 Million in the New Year

Investment Highlights

Led by its PUR Biologics division, emerging medtech player HippoFi, Inc., (formerly known as ORHub), is in the early innings of significant revenue growth. The Company has quickly become a go-to player in the multi-billion-dollar Regenerative Therapeutics market.

The PUR product line features popular, innovative products serving unmet needs. The products are designed for use in spine procedures and advanced autologous cell therapies for regenerating cartilages in joints and spinal discs.

ORHB’s sales are driven by its distributor relationships, notably segment leader Precision Spine. The company’s 207 sales distributors now offer the complete PUR biologic line to 280 hospitals and roughly 340 spine surgeons who perform 800 of these surgeries monthly.

PUR has entered a new innovation and evolution phase, which features the development of transformative products that could be awarded 510(k) clearance in 2024.

We currently forecast sales will jump from $2.9M in FY23E to $28M in FY24E and $75M in FY25E. Plus, we project meaningful operating income to commence in FY24E.

Our 12+ month price target of $0.37 reflects a 4x price/revenue multiple on FY25E revenue, the same metric assigned to its peer group. We believe upside exists when taking into account a premium to FY25E sales and a 25x P/E on net income.



This is a strong historical level, and we are seeing increased volume. This is the opportunity we have been waiting for.

We have had strong consolidation off of this strong support zone, often followed by strong rallies

Solid bullish confluence at strong demand zone, that means plenty of upside without unhealthy risk

Increasing volume is the hallmark for all breakouts. We can see this on every previous bullish rally as a signature we now have in place


Target #1: $0.0550 (+37.50%)

Target #2: $0.1081 (+170.25%)

Target #3: $0.1353 (+238.25%)

Target #4: $0.2002 (+400.50%)

Support: $0.0231




The View From 30,000 feet

Numerous healthcare technology firms showcase impressive innovation, presenting promising technologies and approaches that, although beneficial, may take years to translate into sales. What sets HippoFi, Inc. (OTCPK: ORHB), formerly known as ORHub, apart is not only its innovative prowess in a crucial therapeutic sector but also the substantial growth experienced by its key subsidiary, PUR Biologics. This growth can be attributed not only to the excellence and diversity of its products but also to the robust network of distribution partnerships. Despite the remarkable achievements and the current undervaluation of the company, largely overlooked by the investing public, we believe that the relatively low valuation is a result of the early stage in the product sales cycle. The subdued average daily volume supports this viewpoint. However, as quarterly financial reports emerge and guidance is provided, there is a potential for these shares to attract aggressive accumulation.

An overview

HippoFi, Inc. (ORHB) is at the forefront of healthcare innovation, deploying cutting-edge solutions in lucrative markets such as Regenerative Therapeutics through its primary subsidiary, PUR Biologics. Acquired in 2022, PUR specializes in innovative biologic products and proprietary technologies for bone growth in surgical spine procedures, featuring a comprehensive portfolio encompassing patented bioactive cellular matrix compositions and advanced autologous cell therapies. Addressing multi-billion-dollar markets, PUR aims to regenerate cartilage, facilitate bone growth in surgical spine procedures, repair spinal discs, and alleviate back and central neuropathic pain.

HippoFi's strategic partnership with Precision Spine, a leader in the industry segment, has significantly boosted demand and sales for PUR products. Precision Spine, known for its extensive spine implant portfolio, now offers the complete PUR biologic line, providing a one-stop-shopping experience to its 207 sales distributors. This collaboration reaches 280 hospitals and approximately 340 spine surgeons conducting 800 surgeries monthly.

Beyond its core allografts and synthetics, PUR is actively developing novel, patented, and proprietary products related to its segment, anticipating future 510(k) submissions. These products incorporate cell therapy and contribute to pain management. ORHB maximizes its acquisition, in-licensing, and distribution strategies, expanding its portfolio with new FDA-approved offerings on a white-label basis and extending distribution channels for PUR.

Simultaneously, ORHB is in the process of creating innovative business management software to standardize processes at the point of surgical care, enhancing logistics and efficiency. While PUR remains the current revenue driver, the upcoming HippoFi-Pay™ division, set to launch in the FY24E fiscal year starting July 2023, will tap into the same target market and channels. This Software as a Service (SaaS)-based approach is expected to yield significantly higher gross margins for ORHB and potentially make a substantial impact in the calendar year 2024.


The Company did not record substantial revenue from fiscal year 2022 through the first six months of fiscal year 2023E, which concluded in December 2022. During this timeframe, ORHB focused on research and development activities and underwent a strategic shift in its model, particularly following the acquisition of PUR Biologics in late 2022. Once the acquisition was finalized, and relationships with Precision Spine and others were solidified, we believe that PUR commenced meaningful product sales in the March 2023 quarter. Consequently, our revenue forecast for fiscal year 2023E (ending June 2023) is $2.9 million, reflecting only two quarters of business.

Looking forward, we anticipate revenues of $28 million for fiscal year 2024E and $75 million in fiscal year 2025E. This growth is expected to be propelled by existing product lines and relationships, in addition to the timing of a projected 510(k) product and other technologies obtained through licensing agreements. If our projections hold true, the Compound Annual Growth Rate (CAGR) for ORHB from fiscal year 2023 to fiscal year 2025 would be 195%. It is noteworthy that we estimate the potential generation of significant operating income starting in fiscal year 2024, with a projected $2.7 million in this line item, resulting in a 9.7% operating margin. For fiscal year 2025E, we project an operating income and margin of $15.3 million and 20.4%, respectively.


Our price target for the next 12 months is $0.37, calculated at 4.0 times the projected $75 million revenue for the fiscal year 2025E ending in June 2025. In the Peer Group analysis in Table III, we observe that the peer group has an average forward 2024 price/revenue multiple of 4.0x, aligning our target with this benchmark. Despite using a revenue figure that is six months beyond the peer group's timeline, we assert that this is justifiable due to ORHB's significantly higher revenue growth rate. It can also be argued that ORHB may merit trading at a premium to the price/revenue multiple. Consequently, employing a 5x price/revenue multiple and a 25x P/E on our fiscal year 2025E revenue and net income forecasts yields a $0.47 price target, which is consistent with metrics observed among leading players in the segment. Consequently, we believe there is potential for substantial future upside to our target.




The American Academy of Orthopaedic Surgeons (AAOS) defines the industry segment as follows:

"Orthobiologics are substances utilized by orthopaedic surgeons to enhance the healing of injuries, accelerating the recovery of fractured bones and injured muscles, tendons, and ligaments. These products are derived from natural substances found in the body, and when employed in higher concentrations, they have the potential to expedite the healing process."

Over the past 15-20 years, the development and utilization of biologics have seen significant growth, driven in part by advancements in stem cell research. Generally, orthopedic biologics are treatments that are isolated or derived from natural sources like human or animal stem cells, plasma, or tissues through innovative technologies. An example of a well-known biologic treatment, once widely publicized, involves injecting platelet-rich plasma (PRP). In this procedure, blood heavily concentrated with platelets from either the patient or a donor is injected into a affected joint.

Market Trends

Notably, a convergence of factors is propelling the expansion of this market. These factors encompass:

  1. Progress in healthcare, particularly in the realm of bone growth stimulation.
  2. Escalating instances of orthopedic disorders resulting in fractures.
  3. An aging population contributing to the market's growth.
  4. A surge in sports-related injuries.
  5. Increasing acceptance and use of orthobiologics materials.
  6. A heightened demand for outpatient surgical procedures.

Growth factors play a crucial role in cell signaling during the healing process, facilitating cellular functions. They are utilized in combination with bone grafts to promote healing. Stem cells, previously associated with limited data and safety information, particularly in areas requiring repair, are now gaining wider acceptance, particularly in the case of autologous bone marrow cells, an area where the Company specializes.

In the realm of orthopedic surgery, there is currently a lack of widely used products for cartilage repair, bone healing enhancement, and reduction of non-unions. The standard of care for such injuries involves maintaining the repair through the application of casts, traction, or fixation with plates, screws, or other implants, whether external or internal. The increasing utilization of biologics is anticipated to transform this segment into a market opportunity worth tens of billions in the next five years. Furthermore, as the shift towards biologics continues, a diversified company like PUR is uniquely positioned to emerge as a leader in the market.



Pur Biologics: The Crown Jewel

In 2022, ORHB successfully acquired PUR for $8.5 million, a strategic move that included obtaining three valuable patents:

Patent #1: Method and compositions for manufacturing ECM (Extracellular Matrix)

Patent #2: Methods of manufacturing and compositions of cell-conditioned medium and ECM using aspartyl-alanyl-diketopiperazine

Patent #3: Cosmetic methods and compositions for activating epidermal cells using immunological adjuvants

This acquisition marked the establishment of ORHB's Regenerative Therapeutics segment, housing the prominent PUR Biologics subsidiary. Positioned as the flagship within the ORHB portfolio, PUR has positioned the Company in the global medical device market, which is projected to reach $445.1 billion by 2026. Notably, PUR is strategically targeting three major categories—hip, knee, and spine—in the US, representing a combined market opportunity of $48 billion.

In this context, ORHB is already distributing PUR's exclusive technologies and a comprehensive array of nearly two dozen products through its network of distributors. These products are designed to regenerate cartilage, alleviate pain, and address the biological origins of degenerative disc disease and osteoarthritis in joints. Notably, the Company has a comprehensive biologic product line tailored for spinal applications.

Capitalizing on licensed patents and employing a platform-oriented approach, PUR is in the process of developing next-generation iterations of its existing products to cater to critical, unmet needs, ultimately enhancing surgical outcomes in cartilage and bone repair/growth. The Company's cost-effective platform technology not only accelerates healing but also holds the potential to reduce costs for hospitals. Additionally, the management's vertically integrated manufacturing strategy could potentially lead to profit margins surpassing industry averages.

PUR has successfully addressed the challenges associated with manufacturing Extracellular Matrix (ECM) from cadaveric allograft tissues, mitigating risks such as disease transmission from emerging viruses like Zika and SARS-CoV-2 (COVID-19). Unlike legacy technologies that rely on multiple human tissues, often obtained from newborn foreskin fibroblasts, PUR scientists have harnessed the potential of Induced Pluripotent Stem Cells (IPSC) to create a safer and single-tested donor source for ECM-producing fibroblasts under current Good Manufacturing Practice (cGMP).

By effectively expanding one donor tissue sample into a single-sourced Master Cell Bank, which undergoes thorough safety testing and is virus-free, PUR ensures the safety and quality of its products. Additionally, the use of IPSC technology enables the creation of designer cell types for specialized ECM products with enhanced therapeutic and regenerative capabilities. Ongoing research underscores the ECM's role in regulating mechanisms linked to chronic pain, and PUR is actively exploring the application of its ECM technology in addressing chronic pain and the opioid crisis stemming from recent overuse.

Currently, management is expanding its revenue base from synthetic bone grafts and allograft biologics while concurrently developing a pipeline of new products to sustain its impressive sales growth rate. Furthermore, with exclusive manufacturing capabilities providing human ECM biomaterials for new, internally produced items, there is potential for rising profit margins in tandem with increasing order sizes in the forthcoming quarters.

Harnessing the awarded patents and those currently pending, PUR is poised to embark on a new phase of innovation and evolution. This phase involves the development of several transformative products with the potential to secure 510(k) clearance. Among the new products in the pipeline are regenerative medicine applications in cell therapy and traditional medical devices utilized by orthopedic surgeons, all contributing to the overall revenue.

One particularly promising 510(k) product under development is nearing completion, featuring the prototype and clinical testing of a Bone Marrow Aspirate Device (BMAD) solution designed for bone and cartilage growth. In the research and development stage, this patented device activates immune cells from a patient's own bone marrow cells at the Point of Care, combining the marrow aspirate with a solid matrix for bone void filling—a common requirement in orthopedic surgeries. The BMAD, alongside a second version, has the potential to significantly enhance the activity and widespread use of stem cells in future Bone Marrow Aspirate (BMA) therapies.

This technology has the ability to prime and activate immune cells, even in the bone marrow of older patients, which still retain the capacity to differentiate into therapeutic cell types. Notably, this addresses the decline that naturally occurs with aging, generating meaningful numbers of MSCs, M2 Macrophages, and T-Memory Cells. This disruptive device technology provides a solution to the challenges associated with centralized factories producing immunotherapies, leading to significantly reduced costs compared to treatments that require such centralized facilities and intricate logistics—costs that often range from $100,000 to $1,000,000 per treatment.

In essence, PUR's products in development are tailored to regenerate cartilage and bone, with a specific focus on repairing cartilage and spinal disc degeneration, as well as addressing osteoarthritis. The inherent characteristics of the product platform have prompted management to explore the creation of what could potentially be the first orthobiologic product addressing pain and addiction. PUR envisions that this innovative offering could potentially decrease the reliance on opioid pain management drugs, thereby potentially reducing the incidence of opioid addiction—a significant health crisis in the nation. This product is expected to undergo FDA clearance in the next 18-24 months.

The Regenerative Medicine Advanced Therapy (RMAT) biologic product is manufactured from iPSC-derived fibroblast ECM, accompanied by a next-generation BMA solution and a novel personalized cell-based immunotherapy. These components collectively serve as a cell-based pain therapy, aiming to reduce opioid use. Additionally, a second-generation BMAD is in development as a cell-based pain therapy to address opioid addiction, based on a patented composition of immune cells and the activation of personalized stem cells.


As of April 2023, ORHB boasts an extensive sales force comprising over 300 representatives through various distribution partners, positioning them to potentially market PUR's offerings. Of particular significance is the strategic alliance with Precision Spine, a key player in the spine therapy market. Precision Spine, historically recognized for its comprehensive spine implant portfolio, has become a one-stop shop for customers, thanks to PUR. The collaboration has been facilitated by an advantageous pricing and compensation model, solidifying PUR's position as the preferred producer for Precision Spine and its sales team.

Furthermore, PUR's recent product introductions, namely advanced synthetic offerings such as PURbridge, PURcore, and PURfiberXP, expand the Company's portfolio in the spine sector.

PURbridge addresses the critical need for bone growth in spine procedures, featuring a proprietary bridge-like structure composed of bioactive glass, absorbent Tri-pore NanoCrystals™, and flexible collagen fibers. PURcore, a moldable synthetic with an interconnected micro-pore structure, promotes rapid colonization of the patient's cells and growth factors, facilitating bone regeneration. PURfiberXP, derived from cortical bone fibers, exhibits exceptional bone-forming capacity and is ideal for enhancing bone regeneration in spine patients.

With these innovative products, PUR's complete biologic line is now offered by 207 sales distributors to existing customers, including 280 hospitals and approximately 340 spine surgeons conducting 800 surgeries monthly. Looking ahead, expectations include an FDA submission for the Bone Marrow Aspirate Device (BMAD) in the coming quarters, with potential clearance in late 2024. Simultaneously, management remains focused on introducing new proprietary products, FDA-approved in-licensed offerings for white label sales, and the expansion of the sales and marketing channel.

A recently awarded patent related to technology activating immune cells holds immense value in the portfolio. With the market value of cancer immunotherapy projected to reach $271.84 billion by 2030, this patent catapults PUR Biologics into the realm of cell and immune therapies, paving the way for groundbreaking medical treatments for patients dealing with immune-compromised and chronic pain conditions. By unlocking the full potential of immune cells, PUR aims to create more effective therapies that combat degenerative and diseased conditions, offering new avenues for restoring the immune system's healing capacity.

Looking toward the future, the development of novel business management software by ORHB aims to standardize processes at the point of surgical care, enhancing logistics and efficiency. With PUR being the current cash cow, the forthcoming launch of the HippoFi-Pay™ division during the FY24E fiscal year, starting July 2023, is anticipated. This Software as a Service (SaaS)-based approach is expected to yield significantly higher gross margins for ORHB, potentially making a material impact in calendar year 2024.





Christopher Wiggins, Chairman, Chief Executive Officer

Christopher is serial entrepreneur with over 20 years in C-level leadership and strategic negotiations. He has built multiple successful companies from the ground-up while creating synergistic partnerships that drive value. Christopher has served as Founder, Chairman and Chief Executive Officer of HippoFi, Inc. (formerly ORHub) since 2020 and has also been President and Founder Katalyst Medical, LLC since 2019. He has extensive experience both in corporate and distribution roles with significant medical device manufacturers like Medtronic, Smith & Nephew, Globus Medical, Integra, Precision Spine, Baxter, Zimmer Biomet, and others. He was also a Co-founder of PUR Biologics and from 2013-2022 and served as Co-founder/Inventor of Adaptive Biologix from 2014-2017, prior to its acquisition by Histogen, Inc. (NASDAQ - HSTO). Christopher received a Bachelor of Arts degree from Concordia University, Irvine and an MBA from Pepperdine University.

Ryan Fernan, Head of PUR Biologics

Mr. Fernan, brings direct access to a broad industry network with a proven track record of over 18 years in the medical device and biotechnology industry. Recognized as a frontrunner in sales and product development, Mr. Fernan's career included leadership roles associated with Johnson&Johnson/DePuy Spine, and then Zimmer/Biomet. With a strong entrepreneurial drive, Mr. Fernan also founded OC Surgical, Inc., which became the largest Actifuse distributor in the United States from UK-based orthobiologics company, ApaTech. His successes with Actifuse largely contributed to its purchase by Baxter (NYSE: BAX) for approx. $330M in 2010. Mr. Fernan went on to found PUR Biologics, quickly developing technologies from concept, through pre-clinical trials, to large animal trials in collaboration with the University of Colorado and UCSD, and into initial FDA human clinical trial discussions. These first- generation technologies were negotiated into a successful sale by Mr. Fernan to Histogen, Inc. (NASDAQ: HSTO), while he continued directing the licensing and development of the next generation of cell derived extracellular matrix technologies.

Colton Melby, Executive, Public Company Advisor

A seasoned C-level executive, Board member, entrepreneur and investor with over thirty years of leadership and operational experience with innovative private and public companies. In aggregate, he has taken four companies onto public exchanges with a combined market capitalization of over $1.5B during his tenure. He has served as an advisor to HippoFi since 2022 and its Chairman and CEO of ORHub, Inc. from 2006-2020. As the primary investor of Waytronx, Colton led the purchase of CUI and up-listed to NASDAQ. He played a critical role in doubling sales and market value appreciation to over $300M while successfully raising over $70M from broker/dealers. He is also the Vice-Chairman and former CEO of CEO Quest Resource Holding Corp (NASDAQ:QRHC) from 2012 – 2014. He led Earth911, Inc. public with a merger into QRHC growing the market cap from $20M to over $450M. From 2001-2008 he served as President and COO, BOARD MEMBER of Smith & Wesson. He as the sole financier in the acquisition of Smith & Wesson from Tompkins PLC by Saf-T Hammer, growing the market cap from $70M to over $1B, up-listing to the AMEX and NASDAQ. He has also served as the CEO of Metal-Form, Inc. from 1987 – 1999 where he led the precision aircraft parts manufacturer from a backlog of $30M to over $500M as a prime supplier to Boeing and Bombardier. Under his leadership, it Metal-Form was named manufacturer of the Year 3x by Boeing and 2x by Bombardier. He later negotiated the sale of the company to a large private equity firm in New York.


  • Source 1:
  • Source 2:
  • Source 3:
  • Source 4:
  • Source 5:
  • Source 6:
  • Source 7:
  • Source 8:
  • Source 9:
  • Source 10:
  • Source 11:



Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media Group LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media Group LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at

By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.

This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.

Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.

The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

Compensation: Pursuant to an agreement between Virtus Media Group LLC and Cambridge Consultants Inc, Virtus Media Group LLC has been hired by Cambridge Consultants Inc for a period beginning on 12/12/2023 and ending 12/16/2023 to publicly disseminate information about OTCPK: ORHB via digital communications. We have been paid four thousand dollars USD.